After the Centers for Medicare & Medicaid Services (CMS) brought up reimbursement concerns about Giapreza (angiotensin II), La Jolla Pharmaceutical Co.'s intravenous therapy to increase blood pressure in adults with septic or other distributive shock, investors had cause to worry that the compound wouldn't qualify for a new technology add-on payment (NTAP) under the inpatient prospective payment system (IPPS).